266 related articles for article (PubMed ID: 16166432)
61. Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes.
Wu CC; Chen HC; Chen SJ; Liu HP; Hsieh YY; Yu CJ; Tang R; Hsieh LL; Yu JS; Chang YS
Proteomics; 2008 Jan; 8(2):316-32. PubMed ID: 18203259
[TBL] [Abstract][Full Text] [Related]
62. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
[TBL] [Abstract][Full Text] [Related]
63. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study.
Amati M; Tomasetti M; Scartozzi M; Mariotti L; Alleva R; Pignotti E; Borghi B; Valentino M; Governa M; Neuzil J; Santarelli L
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):163-70. PubMed ID: 18199721
[TBL] [Abstract][Full Text] [Related]
64. [Clinical value of carbohydrate antigen 50 and carbohydrate antigen 242 in the diagnosis of colorectal carcinoma].
Huang CW; Bai L
Di Yi Jun Yi Da Xue Xue Bao; 2002 Dec; 22(12):1116-8. PubMed ID: 12480590
[TBL] [Abstract][Full Text] [Related]
65. A new approach to fecal occult blood testing based on the detection of haptoglobin.
Xing PX; Young GP; Ho D; Sinatra MA; Hoj PB; McKenzie IF
Cancer; 1996 Jul; 78(1):48-56. PubMed ID: 8646726
[TBL] [Abstract][Full Text] [Related]
66. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer.
Fedarko NS; Jain A; Karadag A; Van Eman MR; Fisher LW
Clin Cancer Res; 2001 Dec; 7(12):4060-6. PubMed ID: 11751502
[TBL] [Abstract][Full Text] [Related]
67. Identification of biomarkers for colorectal cancer through proteomics-based approaches.
Tjalsma H
Expert Rev Proteomics; 2010 Dec; 7(6):879-95. PubMed ID: 21142889
[TBL] [Abstract][Full Text] [Related]
68. Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers.
Leman ES; Schoen RE; Weissfeld JL; Cannon GW; Sokoll LJ; Chan DW; Getzenberg RH
Cancer Res; 2007 Jun; 67(12):5600-5. PubMed ID: 17575123
[TBL] [Abstract][Full Text] [Related]
69. Fecal protein markers of colorectal cancer.
Dubrow R; Yannielli L
Am J Gastroenterol; 1992 Jul; 87(7):854-8. PubMed ID: 1615938
[TBL] [Abstract][Full Text] [Related]
70. [Diagnostic significance of cancer procoagulant activity in colorectal cancer].
Kozuszko B; Skrzydlewski Z; Famulski W
Pol Merkur Lekarski; 2000 Mar; 8(45):127-8. PubMed ID: 10870414
[TBL] [Abstract][Full Text] [Related]
71. Identification and assessment of new biomarkers for colorectal cancer with serum N-glycan profiling.
Zhao YP; Ruan CP; Wang H; Hu ZQ; Fang M; Gu X; Ji J; Zhao JY; Gao CF
Cancer; 2012 Feb; 118(3):639-50. PubMed ID: 21853445
[TBL] [Abstract][Full Text] [Related]
72. Use of the novel marker BLCA-1 for the detection of bladder cancer.
Myers-Irvin JM; Landsittel D; Getzenberg RH
J Urol; 2005 Jul; 174(1):64-8. PubMed ID: 15947579
[TBL] [Abstract][Full Text] [Related]
73. Colorectal cancer detection by gold nanoparticle based surface-enhanced Raman spectroscopy of blood serum and statistical analysis.
Lin D; Feng S; Pan J; Chen Y; Lin J; Chen G; Xie S; Zeng H; Chen R
Opt Express; 2011 Jul; 19(14):13565-77. PubMed ID: 21747512
[TBL] [Abstract][Full Text] [Related]
74. An integrated proteomics and metabolomics approach for defining oncofetal biomarkers in the colorectal cancer.
Ma Y; Zhang P; Wang F; Liu W; Yang J; Qin H
Ann Surg; 2012 Apr; 255(4):720-30. PubMed ID: 22395091
[TBL] [Abstract][Full Text] [Related]
75. Novel serum nucleosomics biomarkers for the detection of colorectal cancer.
Holdenrieder S; Dharuman Y; Standop J; Trimpop N; Herzog M; Hettwer K; Simon K; Uhlig S; Micallef J
Anticancer Res; 2014 May; 34(5):2357-62. PubMed ID: 24778043
[TBL] [Abstract][Full Text] [Related]
76. Differential proteomic analysis of renal cell carcinoma tissue interstitial fluid.
Teng PN; Hood BL; Sun M; Dhir R; Conrads TP
J Proteome Res; 2011 Mar; 10(3):1333-42. PubMed ID: 21142074
[TBL] [Abstract][Full Text] [Related]
77. Glutathione S-transferases activity in patients with colorectal cancer.
Nomani H; Ghobadloo SM; Yaghmaei B; Rezvanie NA; Yaghmaei K
Clin Biochem; 2005 Jul; 38(7):621-4. PubMed ID: 15904910
[TBL] [Abstract][Full Text] [Related]
78. Evaluation of human neutrophil peptide-1, -2 and -3 as serum markers for colorectal cancer.
van den Broek I; Sparidans RW; Engwegen JY; Cats A; Depla AC; Schellens JH; Beijnen JH
Cancer Biomark; 2010; 7(2):109-15. PubMed ID: 21178269
[TBL] [Abstract][Full Text] [Related]
79. Overexpression of nicotinamide N-methyltransferase in gastric cancer tissues and its potential post-translational modification.
Lim BH; Cho BI; Kim YN; Kim JW; Park ST; Lee CW
Exp Mol Med; 2006 Oct; 38(5):455-65. PubMed ID: 17079861
[TBL] [Abstract][Full Text] [Related]
80. Optimization of diagnostic ELISA-based tests for the detection of auto-antibodies against tumor antigens in human serum.
Stefatić D; Riederer M; Balić M; Dandachi N; Stanzer S; Janesch B; Resel M; Ler D; Samonigg H; Bauernhofer T
Bosn J Basic Med Sci; 2008 Aug; 8(3):245-50. PubMed ID: 18816257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
